Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death

Area of Science:

• Oncology
• Cell Biology
• Metabolic Pathways

Background:

• Aberrant cancer cell metabolism and cell cycle dysregulation drive tumor growth.
• Both processes are key therapeutic targets in oncology.
• Thyroid hormone receptor interacting protein 13 (Trip13) is an AAA+-ATPase implicated in cell cycle regulation.

Purpose of the Study:

• To investigate the role of Trip13 in linking lipid metabolism to cell cycle regulation in cancer.
• To elucidate the mechanism by which Trip13 depletion induces mitotic cell death.
• To identify biomarkers for predicting response to mitosis-targeting therapies.

Main Methods:

• Hepatocellular carcinoma cell models were used to study the effects of Trip13 depletion.
• Lipid droplet accumulation and its role in mitosis were analyzed.
• Expression levels of perilipin 2 (Plin2) were assessed in relation to cell death.
• Sensitivity to paclitaxel and Trip13 inhibitors was evaluated based on Plin2 levels.

Main Results:

• Trip13 depletion leads to lipid droplet accumulation via the insulin-receptor/Akt pathway.
• Lipid droplets, coated by Plin2, function as microtubule organizing centers, disrupting mitotic spindle polarity.
• Plin2 is essential for multipolar spindle formation, DNA damage, and mitotic cell death.
• Plin2 expression correlates with susceptibility to cell death induced by Trip13 depletion and paclitaxel.

Conclusions:

• Trip13 depletion triggers mitotic cell death through a mechanism involving lipid droplet-mediated spindle disruption.
• Plin2 is a critical mediator in this process and a potential biomarker.
• Plin2 levels can stratify tumor responsiveness to mitosis-targeting agents like paclitaxel and Trip13 inhibitors.